Efficacy and safety of cemiplimab in cutaneous squamous cell carcinoma on chronic wounds: A French retrospective study

Efficacy and safety of cemiplimab in cutaneous squamous cell carcinoma on chronic wounds: A French retrospective study

Background: Chronic wounds increase the risk of the development of cutaneous squamous cell carcinoma (SCC), often resulting in poor prognosis in part because of delayed diagnosis. Cemiplimab, an anti-PD-1 agent, is recommended as first-line treatment for metastatic or locally advanced SCC not eligib...

Full description

Saved in:
Bibliographic Details
Main Authors: M. Antoszczak, E. Maubec, A.-B. Duval-Modeste, A. Jannic, C. Jacobzone-Leveque, R. Lesbazeilles, F. Skowron, D. Solub, J. Ancel, L. Mortier, M. Viguier
Format: Article
Language:English
Published: Elsevier 2024-12-01
Series:EJC Skin Cancer
Subjects:
Squamous cell carcinoma
Immunotherapy
Wounds and injuries
Leg ulcer
Online Access:http://www.sciencedirect.com/science/article/pii/S2772611824002611
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items